PROCALCITONIN TEST IN RHEUMATIC DISEASES
https://doi.org/10.14412/1995-4484-2014-387-392
Abstract
Estimation of serum procalcitonin (PCT) levels is of great interest in rheumatology in both the diagnosis of coinfections
and the differential diagnosis between rheumatic disease activity and the current infectious process.
Objective: to estimate the value of PCT as a specific marker for generalized and local infection in rheumatic patients.
Subjects and methods. A retrospective study investigated the case histories of 100 inpatients examined and treated at the V.A. Nasonova Research Institute of Rheumatology. Serum PCT concentrations were determined by a quantitative electrochemiluminescence assay using a Cobas E 411 analyzer (Roche, Switzerland).
Results. Infectious diseases were diagnosed in 41 of the 100 patients. The infectious process was generalized and local in 11 and 30 cases, respectively. In the patients with generalized infection, the level of PCT was more than 2.0 ng/ml in 81.8% of the cases. In the local infection and non-infection groups, it was below 0.5 mg/ml in 70 and 84.7% of
cases, respectively. In the generalized infection group, the content of PCT was significantly higher (3.6 [2.3; 10.5]) than in the local infection (0.24 [0.15; 0.7]; р = 0.004) and non-infection (0.15 [0.09; 0.26]; р = 0.0001) groups. It did not depend on rheumatic disease activity. C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR)
correlated with PCT concentrations in different patient groups. ROC analysis showed the optimal sensitivity (82%) and specificity (98%) of PCT as a marker of systemic infection only in the rheumatic patients with its concentration of ≥2.3 ng/ml.
Conclusion. The determination of PCT is certain to contribute to the diagnosis of generalized infections and the differential diagnosis of systemic rheumatic diseases and infectious ones.
About the Authors
G. M. Tarasova
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
E. N. Aleksandrova
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
A. A. Novikov
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
References
1. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996–2003. DOI: http://dx.doi.org/10.1097/01.CCM.0000226413.54364.36.
2. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, singleblinded intervention trial. Lancet. 2004;363(9409):600–7. DOI: http://dx.doi.org/10.1016/S0140-6736(04)15591-8.
3. Julian-Jimenez A, Flores Chacartegui M, Palomo de los Reyes MJ, Brea-Zubigaray S. Usefulness of procalcitonin and C-reactive protein in the acute meningitis in the emergency department. Neurologia. 2013;28(3):189–90. DOI: http://dx.doi.org/10.1016/j.nrl.2011.09.009. Epub 2011 Nov 9.
4. Rau BM, Kemppainen EA, Gumbs AA, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg. 2007;245(5):745–54. DOI: http://dx.doi.org/10.1097/01.sla.0000252443.22360.46,
5. Laifer G, Wasner M, Sendi P, et al. Dynamics of serum procalcitonin in patients after major neurosurgery. Clin Microbiol Infect. 2005;11(8):679–81. DOI: http://dx.doi.org/10.1111/j.1469-0691.2005.01205.x.
6. Buhaescu I, Yood RA, Izzedine H. Serum procalcitonin in systemic autoimmune diseases–where are we now? Semin Arthritis Rheum. 2010 Oct;40(2):176–83. DOI: http://dx.doi.org/10.1016/j.semarthrit.2009.10.004. Epub 2010 Feb 4.
7. Trallero-Araguas E, Selva-O’Callaghan A, Vilardell-Tarres M. Serum procalcitonin levels in febrile patients with systemic autoimmune diseases. Curr Rheum Rev 2007;3(2):107–11. DOI: http://dx.doi.org/10.2174/157339707780619403.
8. Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034–42. DOI: http://dx.doi.org/10.1002/art.34512.
9. Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and metaanalysis. Eur J Clin Microbiol Infect Dis. 2013;32(6):807–14. DOI: http://dx.doi.org/10.1007/s10096-012-1812-6. Epub 2013 Jan 21.
10. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1):93–7. DOI: http://dx.doi.org/10.1016/0014- 5793(84)80839-X.
11. Bohuon CA. Brief history of procalcitonin. Intensive Care Med. 2000;26 Suppl 2:146–7. DOI: http://dx.doi.org/10.1007/BF02900727.
12. Moosig F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998;25(8):1531–33.
13. Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004;48(2):199–205. DOI: http://dx.doi.org/10.1016/j.jinf.2003.08.002.
14. Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123–8.
15. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274–6. DOI:http://dx.doi.org/10.1007/BF02962246.
16. Tamaki K, Kogata Y, Sugiyama D, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol. 2008;35(1):114–9.
17. Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28–33. [Lapin SV, Maslyanskiy AL, Lazareva NM, et al. The value of quantitative analysis of procalcitonine in diagnostics of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya laboratornaya diagnostika. 2013;(1):28–33. (In Russ.)]
Review
For citations:
Tarasova G.M., Belov B.S., Aleksandrova E.N., Novikov A.A. PROCALCITONIN TEST IN RHEUMATIC DISEASES. Rheumatology Science and Practice. 2014;52(4):387-392. (In Russ.) https://doi.org/10.14412/1995-4484-2014-387-392
Views:
1894
Email this article 